- Home
- PPCB vs PRFX Comparison
PPCB vs PRFX Comparison
Compare PPCB & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPCB | PRFX |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | Australia | Israel |
| Employees | 2 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PPCB | PRFX |
|---|---|---|
| Price | $0.10 | $2.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 329.1K |
| Earning Date | 05-16-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.58 |
| 52 Week High | $10.69 | $3.71 |
Technical Indicators
Market Signals| Indicator | PPCB | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 32.17 | 61.10 |
| Support Level | N/A | $1.28 |
| Resistance Level | $0.13 | $2.91 |
| Average True Range (ATR) | 0.01 | 0.32 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 1.39 | 92.62 |
Price Performance
Historical ComparisonAbout PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
About PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.